Picard Medical Marks Public Company Milestone by Ringing the NYSE Opening Bell

Rhea-AI Summary

Picard Medical (NYSE: PMI) rang the New York Stock Exchange Opening Bell on December 18, 2025, marking its transition to the public markets as parent company of SynCardia Systems.

The company is the maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada and said the public listing supports advancing its total artificial heart platform, including the fully implantable Emperor system.

Positive

• NYSE listing and Opening Bell on December 18, 2025
• Manufacturer of the world’s first total artificial heart approved by FDA
• Regulatory approval in both U.S. and Canada for total artificial heart
• Parent company of SynCardia, established clinical leadership

Negative

• None.

Key Figures

NYSE opening bell date December 18, 2025 Ceremony marking transition to public company status

Market Reality Check

$1.82 Last Close

Volume Volume 103,769 vs 20-day average 2,521,491 (relative volume 0.04x) suggests limited trading interest pre-announcement. low

Technical Price $2.23 is trading below the $2.70 200-day moving average, indicating a weak longer-term setup before this news.

Peers on Argus

PMI was down 3.04% while peers showed mixed moves: CTKB up 2.34%, LAB up 5.44%, KIDS down 3.51%, and AVMR/ZIMV flat. This points to stock-specific dynamics rather than a broad Medical Devices move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 09	Clinical durability update	Positive	-8.7%	Record 2,900-day SynCardia Total Artificial Heart support highlighted durability.
Dec 03	Conference presentation	Positive	+2.0%	CEO presenting Emperor Total Artificial Heart data at CSI Focus D-HF.
Nov 26	R&D data presentation	Positive	+1.9%	In vitro benchtop data for Emperor Total Artificial Heart at ISMCS 2025.
Nov 19	Clinical milestone	Positive	-6.7%	First in vivo implantations of fully implantable Emperor Total Artificial Heart.
Nov 14	Earnings update	Positive	+10.7%	Q3 2025 results, IPO proceeds and improved losses versus prior periods.

Pattern Detected

Recent PMI news has drawn mixed reactions: positive clinical and earnings updates often moved the stock, but some strong milestones saw negative follow-through, indicating inconsistent pricing of good news.

Recent Company History

Over the last months, PMI has highlighted clinical and corporate milestones, including its IPO proceeds of $19.5M gross and Q3 revenue of $1.19M with narrowed gross loss. It reported first in vivo implants of the Emperor Total Artificial Heart and multiple conference presentations, plus a record 2,900-day support case. Several of these clearly positive updates produced both gains and drawdowns, so today’s bell‑ringing ceremony follows a period of active development but uneven market reactions.

Market Pulse Summary

The stock surged +10.3% in the session following this news. A strong positive reaction aligns with Picard’s recent pattern where clearly positive milestones, such as Q3 results and technical presentations, previously saw gains of up to 10.66%. However, other clinically meaningful updates, including first in vivo Emperor implants, drew negative responses, showing that enthusiasm has not always been sustained. Investors would need to weigh ongoing going‑concern disclosures and reliance on external financing from recent filings when considering how durable any sharp upside move might be.

Key Terms

total artificial heart medical

"maker of the world’s first total artificial heart approved by both the U.S."

A total artificial heart is a surgically implanted mechanical device that replaces the heart’s two main pumping chambers and takes over circulation, acting like a continuous pump that keeps blood moving through the body. Investors care because it is a high-cost, high-stakes medical product whose commercial success depends on clinical trial results, regulatory approvals, hospital adoption, reimbursement rules and long-term patient outcomes — factors that drive revenue potential and risk.

u.s. food and drug administration (fda) regulatory

"first total artificial heart approved by both the U.S. Food and Drug Administration (FDA)"

The U.S. Food and Drug Administration (FDA) is a government agency responsible for protecting public health by ensuring the safety and effectiveness of food, medicines, vaccines, and other health-related products. For investors, the FDA’s decisions can significantly impact companies in the healthcare and food industries, as approval or rejection of products can influence a company's success and stock performance.

health canada regulatory

"total artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada"

Health Canada is the government department responsible for overseeing the safety and regulation of health-related products and services in Canada, including medications, medical devices, and vaccines. Its approval and guidelines help ensure that these products are safe and effective for public use. For investors, Health Canada's decisions can influence the success of healthcare companies and affect the availability of new medical treatments in the Canadian market.

end-stage heart failure medical

"advancing total artificial heart therapy for patients with end-stage heart failure."

End-stage heart failure is the final, severe phase of chronic heart disease when the heart can no longer pump enough blood despite available medicines and procedures, like an engine that keeps failing even after repeated repairs. It matters to investors because this condition drives demand for high-cost treatments (advanced drugs, devices, transplants, and long-term care), influences regulatory and reimbursement decisions, and can shape market opportunities and financial risk for healthcare companies.

AI-generated analysis. Not financial advice.

Picard Medical, Inc. / SynCardia Systems LLC commemorate the Company’s transition to the public markets and continued advancement of their Total Artificial Heart technology

TUCSON, Ariz., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada, today announced that it will ring the Opening Bell at the New York Stock Exchange on December 18, 2025, marking the Company’s transition to the public markets and its continued commitment to advancing total artificial heart therapy for patients with end-stage heart failure.

“We are proud to mark Picard Medical’s transition to a newly public company,” said Patrick NJ Schnegelsberg Chief Executive Officer of Picard Medical. “Our technology has supported patients worldwide and becoming a public company strengthens our ability to advance our artificial heart platform including the fully implantable Emperor system. This marks an important next phase as we build on decades of clinical leadershippioneering the world’s first life-sustaining total artificial heart, advancing our next-generation technology and creating long-term value.”

About Picard Medical and SynCardia

Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.

For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, http://www.sec.gov.

Contact:

Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com

Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com

General/Media
Brittany Lanza
blanza@syncardia.com

FAQ

What does Picard Medical’s NYSE listing (PMI) on December 18, 2025 mean for investors?

The listing marks Picard Medical’s transition to public markets and provides public trading under ticker PMI as of December 18, 2025.

Is Picard Medical’s total artificial heart FDA approved and does PMI operate in Canada?

Yes; the company is the maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada.

What product roadmap did Picard Medical highlight when ringing the NYSE bell (PMI)?

The company said it will advance its total artificial heart platform, including development of the fully implantable Emperor system.

Who leads Picard Medical and commented on the NYSE Opening Bell event?

Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical, commented on the company’s transition to a public company.

What is Picard Medical’s relationship with SynCardia and its clinical experience?

Picard Medical is the parent company of SynCardia Systems, noted for decades of clinical leadership with the total artificial heart.